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Abstract
Background: The adipocyte-derived hormone leptin influences the behaviour of a wide range of cell types and is now
recognised as a pro-angiogenic and pro-inflammatory factor. In the vasculature, these effects are mediated in part through
its direct leptin receptor (ObRb)-driven actions on endothelial cells (ECs) but the mechanisms responsible for these activities
have not been established. In this study we sought to more fully define the molecular links between inflammatory and
angiogenic responses of leptin-stimulated human ECs.
Methodology/Principal Findings: Immunoblotting studies showed that leptin increased cyclo-oxygenase-2 (COX-2)
expression (but not COX-1) in cultured human umbilical vein ECs (HUVEC) through pathways that depend upon activation
of both p38 mitogen-activated protein kinase (p38
MAPK) and Akt, and stimulated rapid phosphorylation of vascular
endothelial growth factor receptor 2 (VEGFR2) on Tyr
1175. Phosphorylation of VEGFR2, p38
MAPK and Akt, and COX-2
induction in cells challenged with leptin were blocked by a specific leptin peptide receptor antagonist. Pharmacological
inhibitors of COX-2, the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and p38
MAPK abrogated leptin-induced EC
proliferation (assessed by quantifying 5-bromo-29-deoxyuridine incorporation, calcein fluorescence and propidium iodide
staining), slowed the increased migration rate of leptin-stimulated cells (in vitro wound healing assay) and inhibited leptin-
induced capillary-like tube formation by HUVEC on Matrigel. Inhibition of VEGFR2 tyrosine kinase activity reduced leptin-
stimulated p38
MAPK and Akt activation, COX-2 induction, and pro-angiogenic EC responses, and blockade of VEGFR2 or
COX-2 activities abolished leptin-driven neo-angiogenesis in a chick chorioallantoic membrane vascularisation assay in vivo.
Conclusions/Significance: We conclude that a functional endothelial p38
MAPK/Akt/COX-2 signalling axis is required for
leptin’s pro-angiogenic actions and that this is regulated upstream by ObRb-dependent activation of VEGFR2. These studies
identify a new function for VEGFR2 as a mediator of leptin-stimulated COX-2 expression and angiogenesis and have
implications for understanding leptin’s regulation of the vasculature in both non-obese and obese individuals.
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Introduction
Angiogenesis, the formation of new blood vessels from pre-
existing vasculature, plays a central role in adult tissue homeostasis
and is an important component of physiological and pathological
processes including wound healing, tissue remodelling, tumour
development and growth of atherosclerotic plaques [1]. Leptin is a
cytokine derived principally from adipose tissue depots, including
perivascular fat, and has multiple biological actions mediated
through interaction with several alternatively spliced cell surface
receptor isoforms. The long form (ObRb) is predominantly
responsible for active signal transduction and functionally active
ObRb has been identified in several peripheral cells and tissues,
including human endothelial cells (EC) [2]. The functional
significance of endothelial ObRb is highlighted by leptin’s ability
to regulate EC proliferation and apoptosis [3,4], to stimulate nitric
oxide synthesis [5,6] and to promote angiogenesis [4,7,8,9].
However, while leptin has been implicated as a regulator of both
physiological and pathological angiogenesis and its pro-angiogenic
properties are generally accepted [7,10], the molecular basis of
these actions is not yet defined and precisely how leptin regulates
the pro-angiogenic functions of ECs remains unclear. Under-
standing these signalling mechanisms is of fundamental impor-
tance because aberrant signalling through ObRb in pathological
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which may extend peripherally to the endothelium.
A close association between inflammation and angiogenesis
has recently been established and these processes are now
recognised to play interdependent roles in orchestrating tissue
repair and tumourigenesis. A role for leptin in inflammation is
supported by reports of its direct modulation of monocyte,
macrophage and T cell signalling and function [11,12,13]. In
keeping with its ability to influence inflammatory processes and
to promote angiogenesis, there is also evidence that leptin is
chemotactic for both neutrophils [14] and endothelial cells [15].
One important pathway regulating the synthesis of key
inflammatory molecules with potential importance in physiolog-
ical/pathological angiogenic processes involves the cyclo-oxy-
genase (COX) enzymes. COX enzymes catalyse the committed
step in prostanoid synthesis, converting free arachidonic acid
into the prostaglandin (PG) precursors PGG2 and PGH2.T h e
actions of tissue-specific terminal PG synthases [16] then catalyse
the formation of prostanoids, including prostacyclin (PGI2), from
PGH2. COX-1 is constitutively expressed by most cell types
whereas COX-2 is generally absent, or present at low levels, but
can be induced by pro-inflammatory and mitogenic stimuli
[17,18]. Leptin, for example, has been documented to promote
COX-2 induction in both macrophage and adenocarcinoma cell
lines [11,19]. There is also growing evidence for the involvement
of COX-2-derived mediators in angiogenic processes, particu-
larly tumour angiogenesis, and in keeping with this role non-
steroidal anti-inflammatory drugs that selectively block COX-2
activity have both anti-angiogenic and anti-carcinogenic actions
[20,21]. The potential effects of leptin on pro-inflammatory
signalling and gene expression in human ECs have received little
attention, but regulation of COX-2 induction and activity could
represent a key mechanism contributing to leptin’s angiogenic
actions.
Here, we have investigated the relationship between pro-
inflammatory and pro-angiogenic actions of leptin in human ECs.
We show that leptin enhances endothelial COX-2 expression
through mechanisms that depend upon activation of p38
MAPK and
phosphatidylinositol 3-kinase (PI3K)/Akt. We also provide
evidence that the activities of p38
MAPK, PI3K/Akt and COX-2
are required for leptin-mediated angiogenic activity and that
phosphorylation of vascular endothelial growth factor receptor 2
(VEGFR2) on Tyr
1175 is upstream of leptin-induced p38
MAPK/
PI3K/Akt activity, COX-2 induction and the associated angio-
genic responses. Together, these studies suggest that a functional
endothelial p38
MAPK/Akt/COX-2 signalling axis is required for
leptin’s pro-angiogenic actions and that this is mediated, at least in
part, by ObRb-dependent activation of VEGFR2. These studies
highlight the importance of leptin as a direct modulator of EC
function and suggest a novel interaction between leptin- and
VEGF-induced signalling in human ECs that has functional
significance for the regulation of leptin’s angiogenic activity.
Materials and Methods
Ethics Statement
Human umbilical cord collection (obtained with informed
written consent) conformed to the principles outlined in the
Declaration of Helsinki and was approved by East London and
The City Local Research Ethics Committee (ref. no. 04/Q0604/
4). Experiments conducted on the developing extra-embryonic
vasculature (chorioallantoic membrane; CAM) of the chicken
embryo commenced and were completed before day 10 of
development and thus did not require ethical approval.
Materials
Human recombinant leptin was purchased from Peprotech
(Rocky Hill, USA). Human a-thrombin, bovine serum albumin
(BSA; fraction v), and polyvidinylidene membranes (Immobilon-
p
TM) were all purchased from Sigma (Dorset, UK). Human
recombinant VEGF-A165 and the VEGFR2 blocking antibody
were from R&D Systems (Oxford, UK). Endothelial cell growth
factor (ECGF) was from Upstate (Millipore; Durham, UK) and
growth factor-reduced Matrigel was obtained from BD Biosci-
ences (Oxford, UK). SB202190, NS398, LY294002 and SU4516
were all from Calbiochem (Nottingham, UK). Polyclonal
COX-1, COX-2, phospho-Akt (Ser
473)a n dp 3 8
MAPK antibodies
were all purchased from Santa Cruz Biotechnology (Santa Cruz,
CA) and the ObRb (rabbit polyclonal) antibody was from
Abcam (Cambridge, UK). Anti-phospho-p38
MAPK antibody was
purchased from Biosource (Nivelles, Belgium), and antibodies
against phosphorylated VEGFR2 (Tyr
1175), VEGFR2, phospho-
tyrosine, phospho-GSK3b and Akt were from Cell Signalling
Technology (Hertfordshire, UK). Horseradish peroxidise-conju-
gated goat anti-rabbit and rabbit anti-goat antibodies were
obtained from Pierce (Rockford, USA). Reagents for SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) were purchased
from Bio-Rad (Hemel Hempstead, Hertfordshire, UK) and
National Diagnostics (Hessle, Hull, UK). The bicinchonic acid
(BCA) protein assay was from Pierce (Rockford, USA). Culture
media were purchased from Sigma, PAA Laboratories (Somer-
set, UK) or BDH. The BrdU ELISA kit was purchased from
Roche Diagnostics (Mannheim, Germany), calcein AM and
propidium iodide from Invitrogen (Paisley, UK), and all other
reagents from Sigma or BDH at the equivalent of AnalaR grade.
The leptin peptide receptor antagonist 2 (LPrA2) was synthe-
sised and purified as described elsewhere [22] and dissolved in a
sterile filtered vehicle solution (0.0025% dimethyl sulfoxide in
PBS).
Endothelial cell (EC) culture
Human umbilical vein ECs (HUVEC) were isolated and
cultured as described in previous publications [18,23]. Briefly,
cells were grown in medium M199 supplemented with 20% FCS,
4 mM glutamine, 100 units/mL penicillin, 100 units/mL
streptomycin and 20 mM NaHCO3 and cultured at 37uCi n5 %
CO2/95% air in 25 mm
2 tissue culture flasks pre-coated with 1%
gelatin (w/v). When confluent, cells were passaged into 75 mm
2
tissue culture flasks and cultured in M199 (as above) containing
20 mg/mL ECGF. Unless stated otherwise, cells were used
routinely at passage 2. Experimental incubations were carried
out in Hepes-buffered medium M199 with or without 10% FCS
and 10 mg/mL ECGF as indicated.
Stimulation of ECs with leptin
In all experiments ECs were exposed to human recombinant
leptin at final concentrations of 1, 10 and 100 ng/mL for the
times indicated in the figure legends, and the effects of leptin
compared directly to those of VEGF165 (25 ng/mL). The leptin
concentration evoking a maximal effect on the signalling and
functional responses investigated differed among HUVEC
isolates (data not shown), demonstrating that primary human
ECs display variable sensitivity to leptin. Despite this variation,
the level of stimulation observed was highly consistent across
experiments. Thus, values used to generate the means for
statistical analyses were those representing the maximum
response to leptin for each experiment within a group (n=3–15
individual cell isolates).
Mechanisms of Leptin-Stimulated Angiogenesis
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iodide staining
HUVEC (20,000/well) were seeded onto 24-well plates and
cultured for 6–14 hours. Cells were starved (12–16 hours) in serum-
and ECGF-free M199 and subsequently exposed to agonists prepared
in Hepes-buffered M199 as detailed in the figure legends. Following
incubation at 37uC for 24 hours, the medium was removed, the cells
washed twice with PBS/0.5% BSA and then fixed in PBS/4%
paraformaldehyde. Fixed cells were washed in PBS and a solution of
propidium iodide (1 ng/mL in PBS) was added (500 mL/well). Nuclei
were visualised using a Zeiss LSM 510 confocal microscope and 12
fields per well were analysed using a purpose-designed macro.
Measurement of VEGF165 release
VEGF165 in supernatants from HUVEC exposed to leptin (1–
100 ng/mL) for times ranging between 5 minutes and 24 hours was
measured by sandwich ELISA. 96-well microtiter plates were coated
with 100 mL/well of goat anti-human VEGF165 (0.4 mg/mL) buffered
with50 mM sodiumbicarbonate (pH 9.6) and incubated overnightat
4uC. Plates were then incubated with 1% BSA in PBS for 1 hour at
room temperature to restrict non-sp e c i f i cb i n d i n g .H u m a nr e c o m b i -
nant VEGF165 standards or samples were added to the wells (100 mL/
well) and incubated for 2 hours at room temperature. Biotinylated
goat anti-human VEGF165 (0.2 mg/mL; 50 mL/well) was added and
incubations carried out for 2 hours at room temperature. A colour
reaction was induced by the addition of tetramethylbenzidine/
hydrogen peroxide substrate solution (100 mL/well) and was stopped
30 minutes later by addition of 1 M sulphuric acid (50 mL/well). The
optical density (OD) at a wavelength of 405 nm was then measured
using a Wallac Victor
2 1420 multilabel counter. The OD of the
standards in serum-free medium (0.25–5 ng/mL) was used to
calculate the concentration of VEGF165 in the sample.
Western blotting
Confluent HUVEC in 60 mm
2 dishes were serum- and ECGF-
starved for 16 hours. Quiescent cells were then subjected to
treatments as detailed in the figure legends. Whole cell lysates were
prepared and analysed by SDS-PAGE and immunoblotting as
described [23]. Immunoreactive proteins were visualised by
enhanced chemiluminescence and densitometric analysis of
immunoblots was performed using a Bio-Rad scanning densitom-
eter and Quantity One analyzing software.
Immunoprecipitation
Confluent HUVEC in 60 mm
2 dishes were serum-starved (10–
12 hours), treated with vehicle, leptin or VEGF (5 minutes) and
lysed on ice in a buffer (pH 7.4) composed of 50 mM Hepes,
10 mM sodium pyrophosphate, 100 mM NaF, 2 mM EDTA,
2m MN a 3VO4, 1% Triton (v/v), 10% glycerol (v/v), 0.5 mM
phenylmethanesulphonylfluoride, 10 mg/mL aprotinin and 10 mg/
mL leupeptin. Equal quantities of cell lysates (200 mg) were
incubated (4uC) with VEGFR2 antibody (2 mg) overnight, with
rotation. Protein A-sepharose (50 mL) diluted 1:1 in PBS was then
added and rotation continued for 1 hour. The resulting immuno-
precipitates were washed three times by centrifugation followed by
resuspension in ice-cold PBS. Sample buffer (20 mL; Tris HCL
100 mM (pH 6.8), 20% (v/v) glycerol, 4% (w/v) SDS, 0.1% (w/v)
bromophenol blue, 10% (v/v) b-mercaptoethanol) was added to the
precipitates prior to analysis by SDS-PAGE and western blotting.
Wound-migration assay
An in vitro wounding assay was used to measure directional EC
migration. HUVEC were seeded onto gelatin-coated 24-well
plates and allowed to form confluent monolayers. Cells were then
cultured in reduced serum/growth factor medium (M199: 10%
FCS; 10 mg/mL ECGF) overnight and pre-treated with the
appropriate agonist in 10% FCS and 5 mg/mL ECGF in M199
for 6 hours. Monolayers were scratch wounded using a sterile
200 ml pipette tip. Cells were washed with PBS and agonists/
inhibitors added in 0.5 mL of medium containing 10% FCS and
5 mg/mL ECGF. The plate was then placed in the temperature-
controlled chamber (37uC; 95% air, 5% CO2) of a Zeiss confocal
microscope (LSM 510 Meta Axiovert 200 M). The software was
programmed to capture an image of each well at the same wound
location every 30 minutes for 15–19 hours and the rate of
migration assessed by measurements of wound width using the
Zeiss software.
Matrigel assay
Measurements of capillary-like tube formation by HUVEC
were achieved using an in vitro assay of EC differentiation on
Matrigel. HUVEC were cultured in M199 containing 5% FCS
and 5 mg/mL ECGF overnight. Growth factor-reduced Matrigel
was plated onto 96-well plates (65 mL/well) and incubated at 37uC
for 30 minutes. HUVEC were seeded at 10,000/well (in M199
containing 5% FCS/5 mg/mL ECGF; 200 mL/well and the
appropriate experimental treatments), in duplicate. After 8 hours
the medium was removed, the cells washed twice in PBS and
fixation carried out in 4% paraformaldehyde (in PBS). Images
were captured using a Leica DMIRB inverted microscope. Tube
formation was quantified by counting the total number of
interbranches in each well using Leica QWin Imaging software.
Chick chorioallantoic membrane (CAM) assay
To assess the roles of VEGFR2 and COX-2 activities in leptin-
mediated angiogenesis in vivo we used our chick CAM vascularisa-
tion assay [24]. Fertilised white Leghorn eggs were incubated at
37uC in a humidified incubator and windowed. On day 7 of
development, sterile filters soaked with either vehicle, leptin (1 mg/
disk) or VEGF (100 ng/disk) in the presence or absence of SU5416
or NS398 (10 mg/disk) were applied to relatively avascular regions
of the CAM. CAMs were fixed (4%paraformaldehyde inPBS)in ovo
on day 9 and photographed in the localised area of the filter. The
newly capillarised area in the region of each filter was quantified
using Leica QWin Lite software and neovascularisation is expressed
as an angiogenic index (n=12–15 eggs per treatment).
Statistical analysis
One-way ANOVA, repeated measures ANOVA (with Bonfer-
roni post hoc test) or unpaired Student’s t test, as appropriate, were
used to compare means of groups of data using GraphPad Prism
version 5. Within each experiment treatments were performed in
triplicate and the average value treated as a single data point. Data
are expressed as mean 6 SEM, where n is the number of
individual experiments, each performed on a different HUVEC
isolate; p values equal to or less than 0.05 on two-sided tests were
considered statistically significant.
Results
Leptin promotes COX-2 expression and prostanoid
synthesis in human ECs
To determine whether leptin triggers pro-inflammatory path-
ways in ECs we initially examined COX enzyme expression.
Leptin (1–100 ng/mL) had no effect on COX-1 expression
(Figure 1A) but elicited a time-dependent induction of COX-2
mRNA (Figure S1 and Text S1) and protein with maximal up-
Mechanisms of Leptin-Stimulated Angiogenesis
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to that induced by VEGF-A165 (VEGF; 25 ng/mL) (Figure 1A)
[17]. These changes were accompanied by enhanced synthesis of
6-keto-PGF1a and PGE2, but not TxB2 (Figure S2), demonstrating
that leptin increases endothelial COX-2 expression and stimulates
prostanoid synthesis and release.
Leptin-induced COX-2 expression is regulated by
p38
MAPK and Akt
COX-2 expression in ECs depends upon MAPK signalling
pathways with p38
MAPK playing a prominent role [25]. Leptin
enhanced p38
MAPK phosphorylation (Figure 1B) in a time-
dependent manner (data not shown) with maximal activation
evident after 10 minutes. The selective p38
MAPK inhibitor
SB202190 concentration-dependently decreased COX-2 protein
expression in leptin- and thrombin-stimulated cells (Figure 1C;
concentration data not shown). In addition, in keeping with our
recent findings [26,27], HUVEC exhibited some basal COX-2
expression which was also reduced by SB202190 treatment (data
not shown). These data show that leptin-induced COX-2
expression, in common with induction by other pro-inflammatory
agonists, is regulated by p38
MAPK activation.
There is evidence that PI3K/Akt may be important in
mediating some of leptin’s peripheral effects [6,15,28] so we
determined whether leptin activates Akt in ECs and investigated
its potential role in COX-2 induction. Akt phosphorylation was
enhanced in cells exposed to leptin (Figure 2A) and LY294002, a
PI3K inhibitor which blocks downstream Akt phosphorylation
(data not shown), reduced leptin-induced COX-2 expression and
inhibited basal COX-2 expression (Figure 2B). p38
MAPK blockade
with SB202190 also decreased leptin-induced Akt phosphorylation
(Figure 2C). Thus, PI3K/Akt and p38
MAPK activities regulate
COX-2 induction in leptin-stimulated ECs.
Pro-angiogenic functions of leptin-stimulated ECs are
p38
MAPK-, Akt- and COX-2-dependent
We next investigated the importance of these pathways for EC
migration,differentiationandproliferation.Inaninvitrowound assay
leptin (1–100 ng/mL) enhanced the rate of wound closure to a
similar extent to that observed in VEGF-treated cultures (Figure 3A
and B). Studies with selective pharmacological inhibitors of COX-2
(NS398), p38
MAPK (SB202190) and PI3K/Akt (LY294002) showed
that EC migration under basal conditions was unaffected by
inhibitor treatment, whereas leptin-induced migration was reduced
by all three treatments (Figure 3C). SB202190 and LY294002, but
not NS398, also significantly decreased VEGF-induced migration
(Figure 3C). Capillary-like tube formation on Matrigel by leptin-
stimulated HUVEC was equivalent to that observed in cells exposed
to VEGF, and both leptin- and VEGF-induced responses were
reduced in the presence of NS398, SB203580 and LY294002
(Figure4A and4B). Similarly,measurements of BrdU incorporation,
mitochondrial enzyme activity status and nuclear propidium iodide
staining showed that leptin and VEGF enhanced EC proliferation to
similar extents (Figure S3) and that leptin- and VEGF-driven
proliferation were abrogated by exposure to NS398, SB202190 or
LY294002 (Figure 4C). Together, these data show that activation of
p38
MAPKandAkt,aswellasCOX-2activity,regulateleptin-induced
EC migration, proliferation and differentiation.
Leptin treatment stimulates VEGFR2 phosphorylation but
not VEGF release
The equivalency of leptin and VEGF’s effects prompted us to
investigate whether leptin utilises VEGFR2 to affect signalling and
Figure 1. Leptin increases COX-2 expression in HUVEC in a
p38
MAPK-dependent manner. Cells were exposed to vehicle alone,
leptin (100 ng/mL) or VEGF (25 ng/mL) for 6 hours (A) or 10 mins (B).
Lysates were analysed by SDS-PAGE and immunoblotting with COX-2 or
COX-1 antibodies (A) and for p38
MAPK activation using an anti-
phospho(p)-p38
MAPK antibody (B). Immunoblots in A are each
representative of 15 separate experiments on cells from 15 umbilical
veins. Data from densitometric analyses of COX-2 expression are given
as mean 6 SEM (n=15). *** p,0.001 versus control. B. Densitometric
analyses of p-p38
MAPK expression from 5 experiments (mean 6 SEM.
* p,0.05 versus controls). C. HUVEC were pre-treated for 30 minutes
with SB202190 (1 mmol/L) and then exposed to vehicle, leptin or
thrombin (1 U/mL) in the continued absence or presence of SB202190
for 6 hours. Analysis of immunoblots from 3 experiments is shown
(mean 6 SEM: * p,0.05; ***p,0.001 versus controls; # p,0.05 versus
leptin; 1 p,0.05 versus thrombin).
doi:10.1371/journal.pone.0018823.g001
Mechanisms of Leptin-Stimulated Angiogenesis
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increased VEGFR2 phosphorylation (Tyr
1175) to a level similar to
that observed in VEGF-treated cells (Figure 5A). To determine
whether leptin-stimulated VEGFR2 Tyr
1175 phosphorylation
depends upon VEGF release from ECs we measured the VEGF
concentrations in medium from leptin-stimulated cells by ELISA.
No significant VEGF was detected in medium from cells exposed
to leptin for 5 minutes, 1 hour, 6 hours or 24 hours (not
detectable, not detectable, 1286109 and 105699 pg/mL/mg
protein, respectively; n=3 individual experiments). Thus, leptin
promotes rapid phosphorylation of VEGFR2 on Tyr
1175 in the
absence of detectable VEGF release.
Role of VEGFR2 phosphorylation in leptin-driven
responses
To examine the role of leptin-stimulated VEGFR2 phosphory-
lation in ECs we used SU5461, an established inhibitor of VEGFR2
tyrosine kinase activity [29]. SU4516 (5 mmol/L) inhibited leptin-
and VEGF-induced proliferation but did not modify basal (Figure
S4) or hepatocyte growth factor (HGF)-induced proliferation (data
not shown). Additionally, SU4516 (Figure 5B) and a VEGFR2
blockingantibody(Figure S5)reducedleptin-and VEGF-stimulated
tube formation, and SU4516 abrogated the increased migration
rate evident in leptin- and VEGF-stimulated ECs (Figure S4).
Leptin- and VEGF-induced phosphorylation of p38
MAPK and Akt,
and of GSK3b (an established Akt substrate), as well as induction of
COX-2 were also attenuated by SU4516 (Figure 5C). These data
strongly suggest that leptin stimulates VEGFR2 activity to promote
intracellular signalling and COX-2 induction, leading to increased
EC proliferation, motility and differentiation.
An ObRb antagonist attenuates leptin’s effects on
VEGFR2 phosphorylation and downstream signalling
To determine whether binding of leptin to ObRb is required for
leptin-stimulated VEGFR2 Tyr
1175 phosphorylation we used a
leptin peptide receptor antagonist (LPrA2) [22]. We confirmed
that HUVEC express ObRb (Figure S6) and showed that in the
presence of LPrA2 (30 mmol/L), leptin failed to promote VEGFR2
phosphorylation while VEGF-induced receptor phosphorylation
was unaffected (Figure 5D). It is well established that leptin
binding to ObRb activates JAK-STAT signalling so to confirm
blockade of leptin binding to ObRb we monitored Stat-3
phosphorylation. In cells treated with LPrA2 leptin did not
promote Stat-3 phosphorylation while VEGF-induced Stat-3
phosphorylation was still evident (Figure 5D). Similarly, exposure
to LPrA2 reduced leptin-stimulated COX-2 induction without
affecting the response to VEGF. These data indicate that leptin-
mediated VEGFR2 phosphorylation and its downstream effects
require binding to ObRb. Leptin-induced VEGFR2 phosphory-
lation does not result from direct receptor association since ObRb
was absent from VEGFR2 immunoprecipitates prepared from
control, leptin- and VEGF-stimulated ECs (Figure S6).
Blockade of VEGFR2 and COX-2 activities inhibits leptin-
stimulated angiogenesis in vivo
To investigate the biological significance of leptin-stimulated
VEGFR2 phosphorylation and COX-2 induction for leptin’s
Figure 2. Akt regulates leptin-induced COX-2 expression. A.
HUVEC were exposed to either vehicle alone or leptin (50 ng/mL) for
30 minutes and cell lysates monitored for Akt activation using a
phospho-Akt antibody. Histograms show densitometric analysis of
immunoblots from 5 individual experiments (mean 6 SEM). B. Cells
were exposed to vehicle or LY294002 (1 mmol/L) for 30 minutes and
then challenged with leptin in the continued absence or presence of
LY294002 for 6 hours. Analyses of immunoblots from 3 separate
experiments are shown (mean 6 SEM). * p,0.05, *** p,0.001 versus
controls; # p,0.05 versus leptin. C. HUVEC were pre-treated with either
vehicle or SB202190 (1 mmol/L) for 30 minutes and then incubated with
vehicle (C) or leptin in the presence or absence of SB202190 for a
further 30 minutes. Histograms show combined analysis of immuno-
blots probed with a phospho-Akt antibody (n=3 individual experi-
ments; mean 6 SEM). *** p,0.001 versus controls; # p,0.05, ###
p,0.001 versus leptin.
doi:10.1371/journal.pone.0018823.g002
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matrigel requires activation of p38
MAPK and Akt, and is COX-
dependent. HUVEC were cultured on growth-factor reduced matrigel
and treated with either vehicle, leptin (1–100 ng/mL) or VEGF (25 ng/
mL) in the presence or absence of 1 mmol/L NS398, SB202190 or
LY294002 for 8 hours. Cells were photographed (magnification:65) and
the number of tubes counted. Each treatment was carried out in
duplicate in 3 separate experiments. A. Representative images; B.
Analysis of tube number expressed as fold increase (6 SEM) compared
to control. *** p,0.001 versus control; # p,0.05, ### p,0.001 versus
leptin; 1 p,0.05, 111 p,0.001 versus VEGF. C. HUVEC were exposed to
vehicle, leptin or VEGF in the presence or absence of NS398, SB202190
or LY294002 for 24 hours. Data are expressed as fold increase in
number of nuclei (n=4 experiments) with duplicate observations per
treatment. *p,0.05, *** p,0.001 versus controls; ## p,0.005 versus
leptin; 11 p,0.005, 111 p,0.001 versus VEGF.
doi:10.1371/journal.pone.0018823.g004
Figure 3. Leptin-stimulated endothelial cell migration is
attenuated by blockade of p38
MAPK, Akt or COX-2 activities.
A. Confluent monolayers of quiescent HUVEC were scratch wounded
and treated with either vehicle (control), leptin (1–100 ng/mL) or VEGF
(25 ng/mL). The rate of wound closure was monitored in real time by
confocal microscopy (B). C. Confluent cells were exposed to vehicle,
leptin or VEGF in the presence or absence of NS398, SB202190 or
LY294002 (1 mmol/L), wounded, and migration monitored (18 h). Data
in B and C are mean 6 SEM of 3 separate experiments with duplicate
observations per treatment. * p,0.05 versus controls; # p,0.05, ##
p,0.005 versus leptin; 1 p,0.05 cells versus VEGF.
doi:10.1371/journal.pone.0018823.g003
Mechanisms of Leptin-Stimulated Angiogenesis
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chick CAM vascularisation assay [24] (Figure 6). Leptin strongly
stimulated new capillary formation, to an extent comparable to
that of VEGF, and this was attenuated by blockade of VEGFR2
activity with SU4516 or by selective inhibition of COX-2 activity
with NS398. These results confirm the relevance of leptin-
stimulated VEGFR2 phosphorylation and COX-2 activity for
leptin-driven angiogenesis in vivo.
Discussion
Leptin is a pleiotropic adipokine with pro-angiogenic actions
mediated by poorly characterised cellular mechanisms. In this
study we tested the overarching hypothesis that the angiogenic
behaviours of leptin-stimulated human ECs depend upon COX-2
activity and require VEGFR2 activation. To test this hypothesis
we investigated whether leptin modifies COX isoform expression
and through which signalling pathways, determined whether this
signalling axis is utilised by leptin to promote angiogenic actions in
ECs, and explored the potential functional interaction between
leptin-mediated signalling and VEGFR2 activation in vitro and in
vivo. We demonstrated that: (i) leptin induces endothelial COX-2,
but not COX-1 expression; (ii) leptin activates p38
MAPK and
PI3K/Akt pathways and both are utilised to regulate COX-2
expression; (iii) leptin enhances proliferation, directional migration
and differentiation of ECs through activation of p38
MAPK/Akt
signalling and through increased COX-2 activity; (iv) leptin causes
rapid VEGFR-2 phosphorylation upstream of p38
MAPK/Akt/
COX-2 and this is required for leptin’s functional effects on ECs
and for leptin-stimulated neo-angiogenesis in vivo.
In accordance with our previous studies [17,18] we confirmed
that VEGF induces endothelial COX-2 expression and show, for
the first time to our knowledge, that leptin at physiological
concentrations promotes COX-2 induction and prostanoid
synthesis, notably PGI2 and PGE2, by human ECs and is
equivalent to VEGF in its capacity to enhance these responses.
Cellular regulation of COX-2 expression occurs in a cell- and
context-specific manner and several signalling pathways have been
Figure 5. VEGFR2 mediates leptin-stimulated activation of p38
mapk and Akt, COX-2 induction and downstream angiogenic
responses. A. VEGFR2 was immunoprecipitated from vehicle-, leptin (1 ng/mL)- or VEGF (25 ng/mL)-treated HUVEC (5 minutes) and immunoblots
probed with an anti-phospho(p)-tyrosine antibody. The blot shown is representative of 3 individual experiments. Whole cell lysates were also
analysed by immunoblotting with phospho(p)-VEGFR2 or total VEGFR2 antibodies. Densitometric analyses of p-VEGFR2 immunoblots from 3 separate
experiments are shown (** p,0.01 versus control). B. Tube formation on matrigel following treatment (8 hours) with vehicle, leptin (1–100 ng/mL) or
VEGF (25 ng/mL) in the presence or absence of SU4516 (5 mmol/L). * p,0.05 and *** p,0.001 versus control; # p,0.05 and ## p,0.005 versus
leptin; 1 p,0.05 and 111 p,0.005 versus VEGF. C. HUVEC were pre-treated with vehicle or SU4516 (5 mmol/L) and then incubated with leptin (10 ng/
mL) or VEGF (25 ng/L) in the continued presence or absence of SU4516 for 10 mins or 6 hours. Blots were probed with antibodies against
phospho(p)-p38
mapk, phospho-Akt, phospho-GSK3b or COX-2 and are representative of 3 separate experiments. D. HUVEC were exposed to vehicle,
leptin (1 ng/mL) or VEGF (25 ng/mL) in the presence or absence of the ObR antagonist LPrA2 (30 mmol/L) for 5 mins or 6 hours. Lysates were
analysed by SDS-PAGE and immunoblotting for phosphorylated forms of VEGFR2 and Stat-3, total VEGFR2 and Stat-3, or COX-1 and -2. Data are
representative of 2–3 individual experiments.
doi:10.1371/journal.pone.0018823.g005
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p38
MAPK, regulate COX-2 expression in ECs exposed to
physiological and pathological stimuli [21,25,27] and leptin has
been reported to influence p38
MAPK activity in non-vascular cell
types [30,31]. Our data show that leptin caused robust p38
MAPK
activation in ECs, and since selective pharmacological blockade of
p38
MAPK activity abrogated COX-2 induction in leptin-stimulated
cells, COX-2 expression in this setting is p38
MAPK-dependent.
There is also evidence that leptin triggers activation of the PI3K/
Akt pathway in ECs [15], but whether this is utilised to regulate
COX-2 induction and/or angiogenic responses has not been
addressed. We show that leptin enhanced Akt phosphorylation
and that inhibition of PI3K activity reduced COX-2 induction,
suggesting that p38
MAPK and PI3K/Akt signalling underlies the
increased COX-2 expression in leptin-stimulated ECs. We have
previously shown that cross-talk between MAPK pathways and
other signalling events is important for regulating andothelial
COX-2 expression and prostanoid synthesis, as well as for
functional responses in other cell types [27,32]. In this study,
inhibiting p38
MAPK activity with SB202190 reduced Akt phos-
phorylation in leptin- and thrombin-stimulated ECs, implying that
p38
MAPK activation is upstream of Akt in agonist-challenged ECs
and suggesting that interaction between p38
MAPK and PI3K/Akt
signalling [33] has potential importance for control of endothelial
COX-2 induction.
Recent studies have described context-specific roles for both
p38
MAPK and Akt in cell growth [19,21,34] but the functional
significance of these pathways in leptin-stimulated ECs is
unknown. Here, we examined the importance of p38
MAPK,
PI3K/Akt and downstream COX-2 activity for in vitro angiogenic
responses of leptin-stimulated ECs. We showed that key
components of angiogenesis (EC proliferation, migration and
differentiation) were abrogated by inhibition of p38
MAPK and
PI3K/Akt, providing clear evidence for the involvement of these
signalling pathways in leptin-stimulated EC growth and motility.
In vitro angiogenic responses were shown to be COX-2-dependent
since selective inhibition of COX-2 activity with NS398 reduced
the extent of EC proliferation, migration and differentiation in the
presence of leptin. Our results therefore provide strong evidence
that leptin’s angiogenic actions in primary ECs depend upon an
intact p38
MAPK/Akt/COX-2 signalling axis. Although very few
studies have addressed the importance of COX enzymes for
leptin’s cellular actions, one previous study reported that NS398
had no effect on EC differentiation on Matrigel [35], a finding
which most likely reflects the use of very high passage ECs with an
altered phenotype. In our study, COX-2 blockade also suppressed
leptin-stimulated neo-angiogenesis in an in vivo vascularisation
assay, further emphasizing the physiological relevance of COX-2
activity for leptin’s angiogenic activity.
Binding of growth factors to their cognate receptors elicits a
range of biological functions in ECs. Pro-angiogenic signalling is
mediated principally through VEGFR2, the primary VEGFR
expressed by vascular ECs. Previous reports indicated that leptin
increases VEGF synthesis and VEGFR2 expression by breast
cancer cells [31] and suggested that leptin and VEGF can
cooperate to promote angiogenesis in vivo [8], but the molecular
basis of this interaction is not characterised. Here, we noted that
leptin’s effects on COX-2 induction and the angiogenic properties
of ECs were both qualitatively and quantitatively equivalent to
those of VEGF, leading us to hypothesise that leptin regulates EC
function through VEGFR2 activation. We found that leptin
treatment caused rapid phosphorylation of VEGFR2 (Tyr
1175)
with maximal phosphorylation evident after 5 minutes. Since
leptin did not promote VEGF release from ECs, and ObRb and
VEGFR2 did not co-immunoprecipitate, our data collectively
suggest that leptin-mediated VEGFR2 phosphorylation most likely
occurs independently of exogenous VEGF and in the absence of
direct ObRb:VEGFR2 association. These findings support the
recent suggestion that EC-derived VEGF does not contribute to
the angiogenic response through autocrine actions [36,37] and
indicate that leptin may regulate receptor phosphorylation
intracellularly and/or through mechanisms that are independent
of extracellular VEGF-A165 binding to VEGFR2.
There is evidence for both ligand-dependent and -independent
transactivation of VEGFR2 by inflammatory and angiogenic
agonists [37,38,39]. Here, the requirement for leptin-ObRb
interaction to enable VEGFR2 activation is demonstrated by
our observation that treatment with LPrA2, a specific ObRb
blocking peptide [22], abolished leptin-stimulated VEGFR2 and
Stat-3 phosphorylation and reduced COX-2 induction, but did
not modify Stat-3 or VEGFR2 phosphorylation in VEGF-treated
cells. Other investigators have shown that leptin indirectly
transactivates erbB2 [40] and stimulates epidermal growth factor
(EGF) receptor phosphorylation in tumor cells [19]. Our novel
observation that leptin’s actions are mediated, at least in part, by
ObRb-dependent VEGFR2 activation therefore lends support to
the hypothesis that growth factor receptor activation is a key
mechanism through which leptin regulates the angiogenic
functions of ECs.
The results of this study clearly show that VEGFR2 plays a role
in transducing pro-angiogenic signalling through the ObRb. Thus,
leptin’s ability to activate p38
MAPK and Akt, induce COX-2
Figure 6. Leptin-induced angiogenesis in vivo is attenuated by
blockade of COX-2 and VEGFR2 activities. Fertilised eggs were
incubated and windowed. On day 7 of development sterile filters
soaked with vehicle, leptin or VEGF in the absence or presence of
SU5416 (SU) or NS398 (NS) were applied to the CAMs (see Methods)
which were photographed 48 hours later; representative images are
shown. Pooled data from 12–15 eggs per treatment are given as
angiogenic index (mean 6 SEM).
doi:10.1371/journal.pone.0018823.g006
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suppressed by blocking the intrinsic tyrosine kinase activity of
VEGFR2 with SU4516. In addition, the physiological relevance of
VEGFR2 activation for leptin’s pro-angiogenic actions is support-
ed by our observations that leptin- as well as VEGF-stimulated EC
proliferation, directional migration and differentiation in vitro were
all abrogated by treatment with SU4516. Use of a neutralising
antibody to VEGFR2 also substantially reduced the ability of both
leptin and VEGF to stimulate tube formation on Matrigel, further
confirming the importance of VEGFR2 and its activity as a
mediator of leptin’s effects on EC differentiation.
In ECs, up-regulation of COX-2 is generally associated with
preferential release of the vasculoprotective mediator PGI2 [27].
We found that leptin enhanced release of both PGI2 and PGE2
from human ECs and, as expected, confirmed our previous studies
demonstrating VEGF-stimulated prostanoid formation [17,18]. It
is unlikely, however, that rapid VEGFR2 activation by leptin
results from immediate prostanoid release, since early prostanoid
generation (,15 min) was not evident in leptin-stimulated ECs,
and inhibition of COX-2 activity with NS398 had no effect on
leptin-stimulated VEGFR2 phosphorylation (not shown). We have
also shown that neither exogenous PGE2 [17] nor iloprost (a stable
PGI2 analogue; not shown) stimulate VEGFR2 Tyr
1175 phos-
phorylation in ECs, providing further support for the suggestion
that leptin/VEGFR2 interactions are mainly upstream of
prostanoid synthesis. The COX-2 products ultimately responsible
for driving leptin’s ability to enhance the angiogenic capabilities of
ECs remain to be fully defined but both PGI2 and PGE2 are
potential candidates since both are produced by leptin-stimulated
cells and in vivo exposure of CAMs to iloprost or PGE2 accelerates
their vascularisation (unpublished data).
Our studies also raise the interesting question of whether
VEGFR2 is required for the full repertoire of leptin’s actions on
ECs. Although these have yet to be completely characterised it is
evident that VEGF promotes von Willebrand factor secretion from
human ECs [41] and enhances adhesion molecule expression [42],
whereas leptin (1–100 ng/mL) does not (unpublished data). Thus,
our current data suggest that ObRb-VEGFR2 crosstalk is
restricted and may be utilised specifically to regulate leptin’s pro-
angiogenic actions.
Detrimental effects of leptin are well-documented and collec-
tively support its involvement in obesity-driven vascular dysfunc-
tion. For example, leptin increases EC expression of pro-
inflammatory/-thrombotic mediators [5], enhances platelet ag-
gregation in vitro [28] and promotes inflammatory angiogenesis
during tumour growth [31]. On the other hand, support for
vasculoprotective actions of leptin is provided by observations that
leptin phosphorylates and activates nitric oxide synthase (eNOS)
[6], causes NO-dependent and -independent vasodilation [43], has
direct cardioprotective and anti-atherogenic actions in mouse
models [44] and improves vein graft performance in humans [45].
Our demonstration that leptin stimulates PGI2 formation may well
suggest additional vasculoprotective roles and, since its angiogenic
actions require COX-2 activity, raises the possibility that leptin
could participate in reparative angiogenesis. Indeed, wound
healing is impaired in leptin-deficient mice [46], leptin enhances
the activity of circulating angiogenic cells [47] and a known
vasculoprotective adipokine (adiponectin) improves hindlimb
blood flow after ischaemia through mechanisms involving
increased COX-2 activity [48].
In summary, we have shown that leptin binding to ObRb results
in phosphorylation of VEGFR2, leading to activation of p38
MAPK
and Akt, COX-2 induction and COX-2-dependent regulation of
proliferation, motility and angiogenesis. Our studies identify
VEGFR2 and COX-2 as key determinants of leptin-stimulated
angiogenesis in vitro and in vivo and ObRb-dependent VEGFR2
activation reveals a new mode of leptin signalling in ECs which
reinforces its importance as an angiogenic factor and establishes
the functional significance of cross-talk with VEGF signalling.
These findings are likely to have implications for leptin’s regulation
of endothelial cell function in both normal and obese individuals.
Supporting Information
Figure S1 Leptin enhances COX-2 mRNA expression in
HUVEC. Confluent quiescent HUVEC were challenged with
vehicle alone, leptin (1–100 ng/mL) or VEGF (25 ng/mL) for 2, 4
and 6 hours. Total RNA was extracted and COX-2 and GAPDH
mRNAs quantified by real-time reverse-transcription PCR (see
Supplementary text S1). Each sample was analysed in triplicate.
Results were normalised to GAPDH expression and are given as
mean 6 SEM (n=4 individual experiments). *p,0.05 versus
control.
(TIF)
Figure S2 Leptin stimulates endothelial 6-keto-PGF1a
and PGE2 synthesis but not TxB2 formation. Confluent
cultures of HUVEC in 24-well trays were exposed to vehicle or
leptin (1–100 ng/ml) for 8 hours (A and C) and 6 hours (B).
Supernatants were collected and assayed for 6-keto-PGF1a (A),
PGE2 (B) and TxB2 (C) using commercially available assay kits (see
Supplemetary text S1). The protein contents of whole cell lysates
were quantified and eicosanoid synthesis calculated as pg/mg
protein. Results are expressed as fold increases compared to time-
matched controls (mean6SEM; triplicate observations in 3
separate experiments). Basal 6-keto-PGF1a and PGE2 release were
47.3640.6 and 2.361.2 pg/mg protein and in leptin-stimulated
cells 1,0826312 and 6.362.5 pg/mg protein, respectively.
*p,0.05 versus control.
(TIF)
Figure S3 Effects of leptin on endothelial cell prolifer-
ation. A and B. Sub-confluent HUVEC in 24-well trays were
exposed to either vehicle (control), leptin (1–100 ng/mL) or VEGF
(25 ng/mL) for 24 hours. Cells were then fixed, stained with
propidium iodide (PI) and nuclei visualised using confocal
microscopy. Each panel is representative of 12 images and each
experiment was carried out in 4 individual cultures. C. Sub-
confluent HUVEC in 96-well tissue culture trays were exposed to
leptin (1–100 ng/mL) for 24 hours. Proliferation was assessed by
measuring BrdU incorporation as described in Supplementary text
S1. B. Subconfluent HUVEC in 96-well tissue culture trays were
challenged with leptin (1–100 ng/mL) or VEGF (25 ng/mL),
incubated overnight and calcein-AM was used to assess cell
viability/proliferation (see Supplementary text S1). Data are
expressed as mean6 SEM (n=4) with 4–6 observations per
treatment (Panel B, C and D). *** p,0.001 versus control.
(TIF)
Figure S4 Blockade of VEGFR2 activity with SU4516
attenuates leptin-driven endothelial cell proliferation
and directional migration. A: Subconfluent HUVEC were
challenged with vehicle (control), leptin (1–100 ng/mL) or VEGF
(25 ng/mL) in the absence or presence of SU4516 (5 mmol/L) for
24 hours. Nuclei were counted as described in Materials and
Methods. B: Confluent cells were exposed to vehicle (control),
leptin (1–100 ng/mL) or VEGF (25 ng/mL) in the absence or
presence of SU4516 (5 mmol/L) and then scratch wounded.
Migration was monitored by confocal microscopy. Data are
expressed as mean 6 SEM. * p,0.05 and *** p,0.001 versus
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PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e18823control; # p,0.05 versus leptin treatment; 1 p,0.05 versus VEGF
treatment.
(TIF)
Figure S5 Leptin-stimulated endothelial cell differenti-
ation on matrigel is inhibited by treatment with a
VEGFR2 blocking antibody. HUVEC (10,000 per well) were
seeded onto 96-well plates coated with matrigel (50 mL/well) and
treated with vehicle, leptin (100 ng/mL) or VEGF (25 ng/mL) in
the presence or absence of a VEGFR2 blocking antibody or an
IgG control antibody (100 ng/mL) for 8 hours. Cells were then
fixed and imaged and the number of tubes/well quantified as
described in Materials and Methods. Data are the mean of 2
individual experiments (duplicate observations per treatment).
(TIF)
Figure S6 Leptin-stimulated VEGFR2 phosphorylation
is not due to an association between VEGFR2 and ObRb.
VEGFR2 was immunoprecipitated from vehicle-, leptin (1 ng/
mL)- or VEGF (25 ng/mL)-treated HUVEC (5 min) and
immunoblots probed with antibodies against ObRb (A), VEGFR2
(B), or b-actin (C). UbP denotes unbound protein sample,
demonstrating that ObRb was detected in ECs and that it was
not co-immunoprecipitated with VEGFR2.
(TIF)
Text S1
(DOC)
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